This is the worst result in the company's
Posted: Sat Jan 04, 2025 4:56 am
BNP's capitalization is $67 billion, while AXA Group's valuation is $77 billion, although investors seem to value the investment direction itself at $5.3 billion. Investments Stock exchanges Deal BNP Paribas AXA Insurance AXA Investment Similar news Xi Jinping Chinese President Meets with American Investors, CEOs, and Academics – What Did the Parties Talk About? 22:40 - 27.03.2024 Microsoft The biggest deals, acquisitions and mergers in the world of 2023 09:42 - 31.
12.2023 Deal The biggest deals of 2024 18:28 - 01.01.2025 NOVO NORDISK shares fell 20% in one day #TECHINFORM - Novo Nordisk's success story; Giorgi Tolordava 21.12.24 01:00 • 360 Danish pharmaceutical giant Novo india fax data Nordisk had a bad day. Its shares fell by almost 20% in the first few minutes of trading, wiping $130 billion off the company's market capitalization.
history and comes on the heels of the latest clinical trial results showing that the company's new weight loss drug, CagriSema, is not performing as well as the company had hoped. Overweight users of the new drug reportedly lost 22.7% of their body weight during the study period, instead of the predicted 25%. Although the difference between the expected and actual results is not large, the fact is that CagriSema is a new generation drug that has not yet appeared on the market, and it is already reporting worse results than Zepbound, created by Novo Nordisk's main competitor, Eli Lilly, whose users are reporting a 23% decrease.
12.2023 Deal The biggest deals of 2024 18:28 - 01.01.2025 NOVO NORDISK shares fell 20% in one day #TECHINFORM - Novo Nordisk's success story; Giorgi Tolordava 21.12.24 01:00 • 360 Danish pharmaceutical giant Novo india fax data Nordisk had a bad day. Its shares fell by almost 20% in the first few minutes of trading, wiping $130 billion off the company's market capitalization.
history and comes on the heels of the latest clinical trial results showing that the company's new weight loss drug, CagriSema, is not performing as well as the company had hoped. Overweight users of the new drug reportedly lost 22.7% of their body weight during the study period, instead of the predicted 25%. Although the difference between the expected and actual results is not large, the fact is that CagriSema is a new generation drug that has not yet appeared on the market, and it is already reporting worse results than Zepbound, created by Novo Nordisk's main competitor, Eli Lilly, whose users are reporting a 23% decrease.